中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

192 records (took 0.032 seconds)

    Sulfur-containing phospholipid derivatives
    61.
    发明申请
    Sulfur-containing phospholipid derivatives 失效
    含硫磷脂衍生物

    公开(公告)号：US20060105987A1

    公开(公告)日：2006-05-18

    申请号：US10518427

    申请日：2003-06-16

    Applicant: Andrew Miller ,  Michael Jorgensen ,  Rolf Berge ,  Jon Skorve

    Inventor： Andrew Miller ,  Michael Jorgensen ,  Rolf Berge ,  Jon Skorve

    IPC: A61K31/739 ,  A61K31/225

    CPC classification number: C07C329/06 ,  A61K9/1272 ,  C07C323/52 ,  C07F9/10

    Abstract: The present invention provides a lipid compound comprising at least one non-polar moiety and a polar moiety, wherein each or at least one non-polar moiety is of the formula X—Y-Z-, wherein X is a hydrocarbyl chain, Y is selected from at least one of S, Se, SO2, SO, and O, and Z is an optional hydrocarbyl group, wherein the polar moiety is of the formula —[C(O)]mPHG, wherein PHG is a polar head group, and wherein m is the number of non-polar moieties.

    Abstract translation: 本发明提供了包含至少一个非极性部分和极性部分的脂质化合物，其中每个或至少一个非极性部分具有式XYZ-，其中X是烃基链，Y至少选自 S，Se，SO 2，SO和O之一，Z是任选的烃基，其中极性部分具有式 - [C（O）] m - PHG，其中PHG是极性头基，并且其中m是非极性部分的数目。

    Piston having centered pin hole and skirt profile
    62.
    发明申请
    Piston having centered pin hole and skirt profile 审中-公开
    活塞具有中心针孔和裙子轮廓

    公开(公告)号：US20060027095A1

    公开(公告)日：2006-02-09

    申请号：US11194429

    申请日：2005-08-01

    Applicant: Andrew Miller

    Inventor： Andrew Miller

    IPC: F16J1/04

    CPC classification number: F02F3/00 ,  F16J1/16

    Abstract: A piston includes a piston body having a longitudinal central axis. A piston head is formed with a plurality of ring grooves and a pair of pin bosses depend from the head and are formed with a pair of pin bores that are centered on a common pin bore axis that intersects the longitudinal axis of the piston. Skirt Portions have outer surfaces with a longitudinal profile that is convexly shaped. A major diameter of the profile lies within ±2 mm of the pin bore axis in both a cold and hot condition.

    Abstract translation: 活塞包括具有纵向中心轴线的活塞体。 活塞头形成有多个环形槽，一对销凸起从头部取向并且形成有一对销孔，其以与活塞的纵向轴线相交的公共销孔轴心为中心。 裙部具有外表面，其纵向轮廓是凸形的。 型材的大直径在冷镦和热状态下均在销孔轴线的±2 mm内。

    Compound
    63.
    发明申请
    Compound 审中-公开
    复合

    公开(公告)号：US20050287202A1

    公开(公告)日：2005-12-29

    申请号：US11159938

    申请日：2005-06-23

    Applicant: Andrew Miller ,  Michael Keller ,  Michael Jorgensen ,  Eric Perouzel

    Inventor： Andrew Miller ,  Michael Keller ,  Michael Jorgensen ,  Eric Perouzel

    IPC: A61K9/127 ,  A61K47/48 ,  A61K48/00

    CPC classification number: A61K47/644

    Abstract: The present invention provides a process for preparing a modified lipid of the formula comprising reacting (I) a compound of the formula; and (ii) a compound of the formula wherein component (ii) is formulated as a liposome; wherein B is a lipid; wherein A is a moiety of interest (MOI) and is a hydrocarbyl group; wherein X is an optional linker group; wherein R1 is H or a hydrocarbyl group; and wherein R2 is a lone pair, H or a hydrocarbyl group. The moiety of interest A may be selected from a carbohydrate moiety, a polymer, a peptide, a glycoprotein, a small biomolecule (such as a folic acid derivative) and a bioconjugate linker.

    Abstract translation: 本发明提供制备下式的改性脂质的方法，包括使（I）式（I）化合物与 和（ii）下式的化合物其中组分（ii）被配制为脂质体; 其中B是脂质; 其中A是感兴趣部分（MOI）并且是烃基; 其中X是任选的连接基团; 其中R 1是H或烃基; 并且其中R 2是孤对的，H或烃基。 感兴趣的部分A可以选自碳水化合物部分，聚合物，肽，糖蛋白，小生物分子（如叶酸衍生物）和生物缀合物接头。

    Human potassium channel genes
    64.
    发明申请
    Human potassium channel genes 审中-公开
    人类钾通道基因

    公开(公告)号：US20050112662A1

    公开(公告)日：2005-05-26

    申请号：US10976644

    申请日：2004-10-29

    Applicant: Andrew Miller ,  Ping Hu ,  Mark Curran ,  Marc Rutter ,  Wang Jian-Yang

    Inventor： Andrew Miller ,  Ping Hu ,  Mark Curran ,  Marc Rutter ,  Wang Jian-Yang

    IPC: C07K14/705 ,  C12N15/12 ,  C12Q1/68 ,  C07H21/04

    CPC classification number: C07K14/705 ,  A01K2217/05

    Abstract: Methods for isolating K+Hnov genes are provided. The K+Hnov nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such as identification of cell type based on expression, and the like.

    Abstract translation: 提供了分离K + Hnov基因的方法。 K + Hnov核酸组合物用于鉴定同源或相关蛋白质和编码此类蛋白质的DNA序列; 在制备调节蛋白质的表达或功能的组合物中; 并研究相关的生理学途径。 此外，体内基因活性的调节用于预防和治疗目的，例如基于表达的细胞类型的鉴定等。

    Cyclic ether acetal PAF antagonists
    70.
    发明授权
    Cyclic ether acetal PAF antagonists 失效

    公开(公告)号：US5637595A

    公开(公告)日：1997-06-10

    申请号：US175411

    申请日：1993-12-30

    Applicant: Mark Whittaker ,  Andrew Miller ,  Stephen A. Bowles

    Inventor： Mark Whittaker ,  Andrew Miller ,  Stephen A. Bowles

    IPC: C07D403/12 ,  C07D405/12 ,  C07D417/12 ,  C07D471/04 ,  A61K31/425 ,  A61K31/44

    CPC classification number: C07D403/12 ,  C07D405/12 ,  C07D417/12 ,  C07D471/04

    Abstract: Compounds of general formula (I), wherein W represents a 5- or 6-membered aromatic heterocyclic ring containing one or more non-quaternised sp2 nitrogen atoms in its ring, which heterocyclic ring may be optionally fused to a benzene ring or to a further 5- or 6-membered aromatic heterocyclic ring containing one or more nitrogen atoms, wherein at least one of the said heterocyclic rings may also contain an oxygen or sulphur atom, and wherein any of the rings may be optionally substituted with one or more substituents selected from --C.sub.1 -C.sub.6 alkyl, --OC.sub.1 -C.sub.6 alkyl, halo, --CF.sub.3 and --CN; Z represents a) a divalent alkanediyl group from 1 to 8 carbon atoms which may be a straight or branched-chain, wherein the said group is either unsubstituted or substituted by one or more substituents selected from hydroxy, --OC.sub.1 -C.sub.6 alkyl, --SC.sub.1 -C.sub.6 alkyl and halo; or b) a divalent alkenediyl or alkynediyl group from 2 to 8 carbon atoms which may be a straight or branched-chain, wherein the said group is either unsubstituted or subtituted by one or more substituents selected from hydroxy, --OC.sub.1 -C.sub.6 alkyl, --SC.sub.1 -C.sub.6 alkyl and halo; R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.6 each represents a hydrogen atom, a --C.sub.1 -C.sub.18 alkyl or a --C.sub.2 -C.sub.18 alkenyl group; or R.sup.3 and R.sup.5 together with the carbon atoms to which they are attached can form a five to ten membered monocycycloalkyl or bicycloalkyl ring which may be optionally substituted with one or more substituents selected from --C.sub.1 -C.sub.6 alkyl, --OC.sub.1 -C.sub.6 alkyl, halo, --CF.sub.3 and --CN; or R.sup.3, R.sup.4 and R.sup.5, R.sup.6 and the carbon atoms to which they are attached form a phenyl ring which may be optionally substituted with one or more substituents selected from --C.sub.1 -C.sub.6 alkyl, --OC.sub.1 -C.sub.6 alkyl, halo, --CF.sub.3 and --CN; X represents a bond, an oxygen atom, a sulphur atom, a --NH-- group, a --N(C.sub.1 -C.sub.6 alkyl)-- group, a --(CH.sub.2).sub.n -- group or a --CR.sup.7 R.sup.8 -- group; n represents an integer of 1, 2 or 3; R.sup.7 and R.sup.8 each represents a --C.sub.1 -C.sub.18 alkyl or a --C.sub.2 -C.sub.18 alkenyl group; or R.sup.3 and R.sup.7 together with the carbon atoms to which they are attached can form a five to ten membered monocycloalkyl or bicycloalkyl ring which may be optionally substituted with one or more substituents selected from --C.sub.1 -C.sub.6 alkyl, --OC.sub.1 -C.sub.6 alkyl, halo, --CF.sub.3 and --CN; or R.sup.3, R.sup.4 and R.sup.7, R.sup.8 and the carbon atoms to which they are attached form a phenyl ring which may be optionally substituted with one or more substituents selected from --C.sub.1 -C.sub.6 alkyl, --OC.sub.1 -C.sub.6 alkyl, halo, --CF.sub.3 and --CN; and their pharmaceutically and veterinarily acceptable acid addition salts and hydrates are antagonists of platelet activating factor (PAF) and as such are useful in the treatment or amelioration of various diseases or conditions mediated by PAF.

Patent Agency Ranking